Article
Dr. Jack Cush reviews the CV advantage to walking, the OA risk with running and the eczema-OA connection; these articles and journal reports from the past week on RheumNow.com.
All News
Article
Does serum urate elevation differ with different types of alcohol consumption? A Japanese study shows beer and wine was associated with high and moderate increases in uric acid but less so with sake.
Article
A number of new reports this month shed new light on old issues in Gout.
Article
Analysis of commercial insurance claims suggests that patients with asthma or atopic dermatitis have a significantly increased risk of osteoarthritis.
Dr. John Cush
Tweet
203 Rheumatology Clinical trials .gov; after 30 mos 17% are unpublished. Published were more likely to be Phase 3 (57% v 29%) or have +primary outcome (65% vs 26%). Unpub authors cite ongoing preparation, sponsor issues, negative results https://t.co/zSxt0W9ZhB https://t.co/k9rCUSel3e
Dr. John Cush
Tweet
Bimekizumab in Hidradenitis Supprativa (HS) - results of 2 phase III BE HEARD I & II trials show Week 16 50% HS Responses to be 48% and 52% (vs PBO 29% and 32%). >75% maintained response out to wk 48; at wk 48, a 75% HS response seen in 55%. https://t.co/ZxJylP7IUk https://t.co/Kmx1dkHycM
Dr. John Cush
Tweet
The EMA Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, regarding the marketing authorisation of deucravacitinib (Sotyktu) in the treatment of moderate to severe psoriasis based on the POETYK PSO-1 & POETYK PSO-2 RCTs https://t.co/KBIYSJVFqu
. https://t.co/nzuHh6v0ua
Dr. John Cush
Tweet
Frunevetmab (Solensia), is a cat-specific mAb against nerve growth factor was FDA approved, for use in CATS, to treat the pain of osteoarthritis. CATS! https://t.co/mqmQ7jzbpj https://t.co/9FrIOAYJwA
Dr. John Cush
Tweet
Abbvie has completed a phase II upadacitinib vs combo elsubrutinib/upadacitinib ( ABBV-599) in active #SLE - M19-130 (SLEek) Phase 2 trial met the primary endpoint SRI-4 response and pred dose<=10 mg qd. No new safety signals - Phase III trial planned https://t.co/1ZiRX3jUGV https://t.co/k0a54QJ9Hi
Dr. John Cush
Tweet
2022 EULAR Recommendations for ANCA-associated Vasculitis
EULAR has published the 2022 update on recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).
https://t.co/kX3dg9DGuw https://t.co/b27CX6Bn0h
Dr. John Cush
Tweet
LAVLI - A New Autoinflammatory Disorder NIH researchers have have described a novel autoinflammatory disorder called "Lyn kinase-associated vasculopathy and liver fibrosis" (LAVLI), based on a mutation in the LYN gene. https://t.co/VWs0YuF4LD https://t.co/7ydA3bb82j
Dr. John Cush
Tweet
Docs' Liking for Knee Injection Tied to Industry Payments
Physicians accepting payments from drug and device companies administered significantly more hyaluronic acid (HA) injections to Medicare beneficiaries for knee osteoarthritis, researchers found.
https://t.co/REtzVjldl2 https://t.co/gfj5cwmVqs
Dr. John Cush
Tweet
Small trial of MTX vs Apremilast in PsA from India. OL, MD blinded RCT of 31 pts (26 completed). 15 APR vs 16 MTX (had more enthesitis, dactylitis); wk 24 responses favored MTX for major cDAPSA (37% vs 20%; p=0.4), ACR20 (56 v 47%;NS) w/ no diff in AE https://t.co/KIItKgCq4w https://t.co/FG3NV2yLuc
Dr. John Cush
Tweet
Single center study of 320 Difficult to Rx RA (D2TRA) pts, found 76 EULAR-D2TRA pts (24%). D2TRA more likely to be lower socio-economic, RF+, have ILD, higher DAS28-CRP and were more likely to respond to rituximab and JAK inhibitors https://t.co/aEvP6WDvQu https://t.co/FQJvo81FbM
Dr. John Cush
Tweet
30 consecutive seropositive (CCP or RF+) early RA pts - 60% had pulmonary abnormalities (PA). PA correlated with presence of neutrophil activation, parameters of inflammation and RF titres. https://t.co/T7CRLzhOMD https://t.co/nYPEw72zOJ
Dr. John Cush
Tweet
Join RheumNow during the month of April as we discuss Women in Rheumatology, the XX Factor.
Sign up to attend our series!
https://t.co/m1E4WkK9Cx https://t.co/8RZNgoqzEI
Dr. John Cush
Tweet
386 pts w/ NPSLE (cerebritis); half (194) were Rx w/ intrathecal MTX+dexamethasone(iMTX); iMTX grp had higher SLEDAI (17 vs 14) & more pulse IV steroids (72% vs 50%). iMTX grp had better survival & NPSLE remission((P=0.042); best w/ ^CSF protein or SZ https://t.co/JsqUrYEwTK https://t.co/np6ntCR9xp
Dr. John Cush
Tweet
Study of 28,544 gout pts examined fracture risk based on achieving T2T w/ urate-lowering therapy (ULT). The 5 yr risk of hip Fx was 0.5% in those achieving target SU level, but was 0.8% for not achieving SUA target (HR 0.66; 95% CI: 0.46 to 0.93). https://t.co/Yw2zOS0g2v https://t.co/VkGSemlIE4
Dr. John Cush
Tweet
199 psoriasis Pts Rx w/ MTX monotherapy. Drug survival at 1, 2, & 5 yrs was 47, 36, & 29%; Avg MTX duration was 10.1 mos. Discontinuation mostly for AE (39.2%), ineffective (38.5%), PSO remission (12.2%). Durability best w/ ^age & dose >15 mg https://t.co/zKP0QCDzE2 https://t.co/35neGlhpE5
Dr. John Cush
Tweet
NHANES US population survey of 3101 adults (age 50yrs) wearing accelerometer in 2005 - looked at mortality in 2019. Compared to non-walkers (<8000 steps), mortality signif lower for walkers (> 8000 steps) 1-2 days/wk (−15%) or 3 - 7 days/wk (−16.5%) https://t.co/o8ved3gfsW https://t.co/pHAOYO6I2X
